IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Seeks to expand regulatory approval in China where IceSense3 has already been approvedCAESAREA, Israel, Jan. 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has submitted a regulatory filing with China's National Medical Products Administration ("NMPA") for the approval of its ProSense® Cryoablat ...